Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and other organs. buff.ly/4gXf6Sj #Lupus #LupusWarrior #lupusawareness #lupuslife #lupusflare #lupusproblems #lupussurvivor

Behind every cancer diagnosis is a unique human story—stories of emotion. On #WorldCancerDay Caribou is sharing the story of the first patient dosed in our CB-010 ANTLER trial. Clink the link below to watch: bit.ly/4ghv9Jz @UICC #UnitedByUnique #CRISPR #lymphoma

This #BlackHistoryMonth, we’re honoring five black pioneers in the fields of #oncology and #immunology. As Caribou continues to advance research in #lymphoma, #multiplemyeloma, #leukemia, and #autoimmune we honor those who have paved the way.

Mark your calendar for fireside chats with our CEO at upcoming investor conferences. More details: bit.ly/3D56wly

Miss the H.C. Wainwright & Co. 3rd Annual Cell Therapy Virtual Conference? Watch the replay here: bit.ly/3WJCFGe

March is #MutipleMyeloma Awareness Month, raising awareness for a cancer that impacts thousands of people. We’re developing CB-011, an #allogeneic #CARTcelltherapy for the treatment of r/r MM. Learn about our CaMMouflage trial: bit.ly/3TKg3Eb

Happy #EmployeeAppreciationDay! We deeply appreciate our Caribou team, #TheHerd, filled with hard-working members dedicated to developing innovative, transformative therapies for patients with devastating diseases. We thank you today and every day for all that you do!

At Caribou, we’re proud to foster an environment that values the brilliant women on our team who are an integral part of #TheHerd. #InternationalWomensDay #WomenInSTEM

Today Caribou announced Steve Kanner, PhD, our chief scientific officer, is planning to retire at the end of June 2025. We are grateful for his 8 years of service to Caribou and wish him all the best.

Caribou is uniquely positioned in H1 2025 with two clinical data milestones anticipated as we rapidly advance our off-the-shelf CAR-T cell therapies. Read our fourth quarter and full year 2024 financial results and business update: bit.ly/3Fk5GSQ $CRBU

Our president and CEO Rachel Haurwitz, PhD, spoke with @biotech2050pod about Caribou's recent progress, highlights from #JPM2025, and Caribou’s 2025 milestones. Listen to the full conversation here: bit.ly/3DESxDu

This Wednesday, our VP of technical operations will present at the BioProcess International US West Conference. For more details and a full schedule, head to the event site: bit.ly/3X82jEI#BPIWest

According to National Cancer Institute, #multiplemyeloma affects ~179,000 people in the U.S., with ~36,000 new patients diagnosed each year. At Caribou, we’re leading a new era of #CARTcelltherapies and patient care for multiple myeloma. Learn more: bit.ly/3TKg3Eb

Caption: Caribou continues to see encouraging data from lead clinical programs in oncology, CB-010 for 2L LBCL and CB-011 for r/r #multiplemyeloma, and has taken actions to prioritize allocation of resources for these two Phase 1 clinical programs. $CRBU investor.cariboubio.com/news-releases/…

Tune into the webcast with Rachel Haurwitz, PhD, at BofA Securities 2025 Health Care Conference. Read here for more details: bit.ly/4iUFw7o $CRBU

Today we reported our Q1 earnings. Learn more in our first quarter 2025 financial results and business update: bit.ly/3SpviRw #CRISPR #CellTherapy $CRBU

We’re headed to the Jefferies Global Healthcare Conference next week for a fireside chat. Learn more: bit.ly/4dBIexv

See you at #ASCO25! Members of our clinical and translational team will be in attendance. We’re looking forward to connecting with clinical leaders in #Lymphoma and #MultipleMyeloma to discuss our ongoing ANTLER and CaMMouflage clinical trials. #CRISPR #CARTCellTherapy

Tune in to a fireside chat tomorrow with our president and CEO, Rachel Haurwitz, PhD, at the Jefferies Global Healthcare Conference. Tune into the webcast here: bit.ly/4jPJm2d #CellTherapy #CRISPR $CRBU

Heading to Boston? Join Caribou’s SVP of translational research, Enrique Zudaire, PhD, as he chairs a session about optimizing dosing & enhancing therapeutic outcomes at the 7th Annual Allogeneic Cell Therapies Summit. Learn more: bit.ly/3SIln9Q #CRISPR #CARTCellTherapy